Skip to main content

Phase 3 Start

GHRS: Phase3_Start: A Double-blind, Randomized, Placebo-controlled, Phase III Study for Reducing Dependency and Cardiovascular Events With Oral Colchicine 0.5mg Once Daily Compared With Placebo in Participants With Spontaneous Intracerebral Hemorrhage and Established, or Risk Factors for, Atherosclerosis

September 30, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date
September 30, 2026
Company
GH Research PLC (GHRS)
BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Start

Phase3_Start: A Double-blind, Randomized, Placebo-controlled, Phase III Study for Reducing Dependency and Cardiovascular Events With Oral Colchicine 0.5mg Once Daily Compared With Placebo in Participants With Spontaneous Intracerebral Hemorrhage and Established, or Risk Factors for, Atherosclerosis

GHRS overview →

Other upcoming events for GHRS

Phase 3 StartPhase3_Start: A Phase 3 Randomized Study Comparing Ramantamig Plus Daratumumab Versus Investigator's Choice of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Phase 3 StartPhase3_Start: A Multicentre, Prospective, Randomized, Open-label, Blinded Endpoint, Clinical Trial Evaluating Subcutaneous Semaglutide in Patients With Acute Ischaemic Stroke Due to Anterior Circulation Large Vessel Occlusion Treated With Endovascular Thrombectomy
Phase 1 StartPhase1_Start: Pilot Radioembolisation Clinical Trial Assessing Safety and Efficacy in Recurrent Glioma (PRECISE)
Phase 2 StartPhase2_Start: A Randomized Trial of Omega-3 Dietary Supplementation, Anti Demodex Eyelid Cleanser, and Standard Eyelid Cleanser for Pediatric Chalazia
Phase 2 StartPhase2_Start: The Effects of SGLT2 Inhibition on Vascular Health and Physical Function in Veterans With CKD